Stock comparison
Genmab A/S
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
Novo Nordisk A/S NVO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 65B | Tie |
| Benjamin Graham | 64C | 61C | GMAB |
| Philip Fisher | 48D | 73B | NVO |
| Peter Lynch | 25F | 57C | NVO |
| Joel Greenblatt | 76B | 56C | GMAB |
| Charlie Munger | 68C | 76B | NVO |
| Terry Smith | 71C | 72C | NVO |
Side-by-side metrics
| Metric | GMAB | NVO |
|---|---|---|
| Market cap | $16.47B | $199.21B |
| P/E (TTM) | 6.2x | 10.4x |
| EV/EBIT | 12.0x | 10.9x |
| ROIC (TTM) | 43.78% | 32.2% |
| Gross margin | 93.88% | 81.85% |
| Net margin | 18.23% | 37.2% |
| Revenue CAGR 5y | -18.45% | 21.72% |
| EPS CAGR 5y | -23.48% | 22.03% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 0.7x+90%
- P/E (TTM)6.2xvs 10.4x+41%
- ROIC (TTM)43.78%vs 32.2%+26%
- Gross margin93.88%vs 81.85%+13%
NVO leads on
- EPS CAGR 5y22.03%vs -23.48%+194%
- Revenue CAGR 5y21.72%vs -18.45%+185%
- Dividend yield4.09%vs 0.0%+100%
- Market cap$199.21Bvs $16.47B+92%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.